A novel class of drugs, antibody-drug conjugates (ADCs), are now rapidly emerging as
highly effective treatments for solid tumours. ADCs conjugate conventional …

Precision oncology comprises the set of strategies that aim to design the best cancer
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …

With the booming development of precision medicine, molecular targeted therapy has been
widely used in clinical oncology treatment due to a smaller number of side effects and its …

Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …

Simple Summary Non-small cell lung cancer treatment has undergone a revolution in the
past decade owing to the discovery of mutations that drive carcinogenesis and the …

Simple Summary By coupling the potency of cytotoxic chemotherapy with the selectivity of
targeted therapy, antibody–drug conjugates represent a unique and rapidly growing class of …

PURPOSE HER2-altered non–small-cell lung cancer (NSCLC) represents a diverse
subgroup, including mutations, amplifications, and overexpression. However, HER2 exon 20 …

Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in
2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical …

Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …